Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Trading Halt (ASX:IIQ)

Description The securities of INOVIQ Ltd (‘IIQ’) will be placed in trading halt at the request of IIQ, pending it releasing an announcement. Unless ASX decides otherwise, the sec...read more

Immutep - Appointment of Non-Executive Director (ASX:IMM)

SYDNEY, AUSTRALIA – 14 February 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - December 2023 (ASX:IIQ)

“Those who know me from my role as Chairman of PolyNovo (ASX: PNV), know how excited I am to lead a company dedicated to saving lives and improving patient outcomes. We all have family and fri...read more

icetana - Delco renewal (ASX:ICE)

Highlights: -- icetana has received a US$168,000 (~AUD$250,000), five year order for its AI software solution from Canadian reseller Delco Security. -- This is the expansion of an existing contrac...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more

icetana - Prosegur renewal (ASX:ICE)

Highlights: -- icetana has received a S$864,000 (~AUD$980,000), three year order for its AI software solution from Prosegur Singapore. -- Deployment (programmed for Q3 FY24) will see the existin...read more

icetana - Quarterly Activities Report (ASX:ICE)

icetana Limited (ASX: ICE) (“icetana” or “the Company” or “we”), a company building artificial intelligence video analytics software to help security and IT&...read more

icetana - Quarterly Appendix 4C Cash Flow Report (ASX:ICE)

To view the Quarterly Appendix 4C Cash Flow Report, download the attached PDF.

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 04 January 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Immutep - Change of Registered Office Address (ASX:IMM)

SYDNEY, AUSTRALIA – 22 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), advises that its registered office and principal plac...read more

Immutep - PEI provides constructive feedback for ph3 lung cancer trial (ASX:IMM)

SYDNEY, AUSTRALIA – December 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developi...read more

Immutep receives A$2.6 million French R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA – 7 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related i...read more

INOVIQ - 2023 AGM CEO Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep Announces Site Expansion for INSIGHT-003 Trial (ASX:IMM)

SYDNEY, AUSTRALIA – November 22, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...read more

Viewing: 16 - 30 of 200 Previous | Next